CN100467060C - 通过瘤内施用乳铁蛋白治疗恶性肿瘤疾病的用途 - Google Patents

通过瘤内施用乳铁蛋白治疗恶性肿瘤疾病的用途 Download PDF

Info

Publication number
CN100467060C
CN100467060C CNB038163918A CN03816391A CN100467060C CN 100467060 C CN100467060 C CN 100467060C CN B038163918 A CNB038163918 A CN B038163918A CN 03816391 A CN03816391 A CN 03816391A CN 100467060 C CN100467060 C CN 100467060C
Authority
CN
China
Prior art keywords
lactoferrin
tumor
rhlf
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038163918A
Other languages
English (en)
Chinese (zh)
Other versions
CN1668326A (zh
Inventor
A·瓦拉哈查里
K·佩特拉克
R·巴斯基
B·奥马利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Publication of CN1668326A publication Critical patent/CN1668326A/zh
Application granted granted Critical
Publication of CN100467060C publication Critical patent/CN100467060C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB038163918A 2002-05-10 2003-05-09 通过瘤内施用乳铁蛋白治疗恶性肿瘤疾病的用途 Expired - Fee Related CN100467060C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37944202P 2002-05-10 2002-05-10
US37947402P 2002-05-10 2002-05-10
US37944102P 2002-05-10 2002-05-10
US60/379,442 2002-05-10
US60/379,441 2002-05-10
US60/379,474 2002-05-10

Publications (2)

Publication Number Publication Date
CN1668326A CN1668326A (zh) 2005-09-14
CN100467060C true CN100467060C (zh) 2009-03-11

Family

ID=29424524

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB038163853A Expired - Fee Related CN100467059C (zh) 2002-05-10 2003-05-09 乳铁蛋白在治疗恶性肿瘤疾病中的用途
CNB038163918A Expired - Fee Related CN100467060C (zh) 2002-05-10 2003-05-09 通过瘤内施用乳铁蛋白治疗恶性肿瘤疾病的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB038163853A Expired - Fee Related CN100467059C (zh) 2002-05-10 2003-05-09 乳铁蛋白在治疗恶性肿瘤疾病中的用途

Country Status (11)

Country Link
US (5) US7901879B2 (enExample)
EP (2) EP2286827A1 (enExample)
JP (2) JP4685443B2 (enExample)
CN (2) CN100467059C (enExample)
AT (1) ATE519499T1 (enExample)
AU (2) AU2003239393A1 (enExample)
CA (1) CA2484656A1 (enExample)
CY (1) CY1111999T1 (enExample)
DK (1) DK1507554T3 (enExample)
PT (1) PT1507554E (enExample)
WO (2) WO2003094952A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
WO2003094952A1 (en) * 2002-05-10 2003-11-20 Agennix Incorporated Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
SI2298338T1 (sl) * 2002-09-16 2012-11-30 Agennix Inc Laktoferinski sestavki in postopki za zdravljenjekožnih ran
EP1581243A4 (en) * 2002-12-06 2008-01-02 Agennix Inc ORAL LACTOFERRIN FOR SEPSIS TREATMENT
AU2003296447A1 (en) * 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
AU2003293500A1 (en) * 2002-12-12 2004-07-09 Agennix Incorporated Lactoferrin in the reduction of pain
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
GB0413954D0 (en) * 2004-06-22 2004-07-28 Altunkaya Ali Compositions for topical treatment
US7183381B2 (en) * 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
US20090202574A1 (en) * 2004-11-19 2009-08-13 Jagat Rakesh Kanwar Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
WO2007022537A2 (en) * 2005-08-19 2007-02-22 Agennix Incorporated Use of lactoferrin as a chemokine and a chemotactic modulator
WO2007103070A2 (en) * 2006-03-03 2007-09-13 Genetronics, Inc. Method and device for treating microscopic residual tumors remaining in tissues following surgical resection
EP2032170B1 (en) * 2006-06-14 2012-11-28 N.V. Nutricia Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof
AU2009293475A1 (en) * 2008-09-19 2010-03-25 Nestec S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
RU2579661C2 (ru) * 2009-01-28 2016-04-10 Жан-Поль ПЕРРОДЭН Способ производства лактоферрина, фракция, содержащая лактоферрин, и ее применения
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
JP2015067560A (ja) * 2013-09-27 2015-04-13 国立大学法人広島大学 ラクトフェリンを含有する癌転移抑制剤
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US9895410B2 (en) 2013-12-12 2018-02-20 Cornell University Methods for preventing and treating oral cancers
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
CN106174462A (zh) * 2016-04-17 2016-12-07 马鞍山市志诚科技有限公司 一种防治血管瘤的营养配方纳米颗粒及制备加工方法
WO2018079701A1 (ja) * 2016-10-28 2018-05-03 株式会社Ｎｒｌファーマ ラクトフェリン活性を有するタンパク質を含む、抗ガン治療補助剤
CN111544579A (zh) * 2020-03-13 2020-08-18 中国农业科学院北京畜牧兽医研究所 一种抗癌症的药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0730868A1 (en) * 1995-02-17 1996-09-11 Tamotsu Satoh Formulated medicines for treatment of oral inflammation, and processed foods to treat and prevent stomatitis
CN1047204C (zh) * 1992-04-24 1999-12-08 贝勒医学院 生产重组人体乳铁蛋白
CN1262625A (zh) * 1997-04-10 2000-08-09 阿吉尼克斯股份有限公司 乳铁蛋白在治疗过敏原诱发疾病中的应用
US6333311B1 (en) * 1997-02-03 2001-12-25 Pharming Useful properties of human lactoferrin and variants thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6351337A (ja) * 1986-08-22 1988-03-04 Snow Brand Milk Prod Co Ltd 抗腫瘍剤
US4977137B1 (en) * 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5766939A (en) * 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5849881A (en) * 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US6100054A (en) * 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5198419A (en) * 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
CA2110899C (en) 1991-06-21 2006-08-08 Jacob G. Michael Orally administrable therapeutic proteins and method of making
JP3184923B2 (ja) * 1992-01-08 2001-07-09 ビオ セレ ラボラトワール エス ア 抗リウマチ剤
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5679807A (en) 1995-01-30 1997-10-21 Hauser, Inc. Preparation of taxol and docetaxel through primary amines
JP3888707B2 (ja) * 1996-01-22 2007-03-07 森永乳業株式会社 血管新生病治療剤
JP3496387B2 (ja) 1996-01-23 2004-02-09 花王株式会社 毛髪化粧料
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
JP2001504447A (ja) * 1996-08-12 2001-04-03 エイプラス サイエンス インベスト アーベー ラクトフェリンおよび／またはラクトフェリシンでの、感染、炎症および／または腫瘍の処置および予防
NZ509101A (en) * 1998-06-26 2003-07-25 N Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
JP2000229881A (ja) 1999-02-10 2000-08-22 Morinaga Milk Ind Co Ltd 癌疾患の予後改善剤
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
US20030096736A1 (en) * 2001-05-09 2003-05-22 Kruzel Marian L. Lactoferrin for age related disorders in humans
WO2003094952A1 (en) * 2002-05-10 2003-11-20 Agennix Incorporated Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
SI2298338T1 (sl) * 2002-09-16 2012-11-30 Agennix Inc Laktoferinski sestavki in postopki za zdravljenjekožnih ran
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
US20090202574A1 (en) 2004-11-19 2009-08-13 Jagat Rakesh Kanwar Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
JP2007233064A (ja) 2006-03-01 2007-09-13 Bitsign:Kk 表示システム及び表示器

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1047204C (zh) * 1992-04-24 1999-12-08 贝勒医学院 生产重组人体乳铁蛋白
EP0730868A1 (en) * 1995-02-17 1996-09-11 Tamotsu Satoh Formulated medicines for treatment of oral inflammation, and processed foods to treat and prevent stomatitis
US6333311B1 (en) * 1997-02-03 2001-12-25 Pharming Useful properties of human lactoferrin and variants thereof
CN1262625A (zh) * 1997-04-10 2000-08-09 阿吉尼克斯股份有限公司 乳铁蛋白在治疗过敏原诱发疾病中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Clin Exp Metastasis. Masaaki Iigo et al,参见第36页左栏第3,4段,表1,表2,表3,第37页左栏RESULF部分第1段,第5段,第39页第,Inhibitory effects of bovine lactoferrin on colon carcinoma26lung metastasisi in mice. 1999 *
JpnJCancer Res. Yoo YC et al,184-90,Bovine lactoferrin and lactoferricin,a peptidederivedffrombovine lactoferrin,inhibit tumor metastasis in mice. 1997 *
中国乳品工业. 唐传核等，44-47，乳铁蛋白最新研究进展-活性多肽以及生理功能（II）. 2000 *

Also Published As

Publication number Publication date
US8242079B2 (en) 2012-08-14
HK1080722A1 (zh) 2006-05-04
US20120276126A1 (en) 2012-11-01
AU2003273182B2 (en) 2009-04-23
WO2003094952A1 (en) 2003-11-20
DK1507554T3 (da) 2011-11-21
US7901879B2 (en) 2011-03-08
ATE519499T1 (de) 2011-08-15
US20040082504A1 (en) 2004-04-29
EP2286827A1 (en) 2011-02-23
EP1507554A4 (en) 2007-05-09
EP1507554A1 (en) 2005-02-23
CN1668326A (zh) 2005-09-14
CN100467059C (zh) 2009-03-11
CN1668325A (zh) 2005-09-14
US20100137208A1 (en) 2010-06-03
CY1111999T1 (el) 2015-11-04
US20110076295A1 (en) 2011-03-31
JP4685443B2 (ja) 2011-05-18
AU2003273182A1 (en) 2003-12-12
EP1507554B1 (en) 2011-08-10
HK1083203A1 (zh) 2006-06-30
JP5156084B2 (ja) 2013-03-06
CA2484656A1 (en) 2003-12-04
US20040009895A1 (en) 2004-01-15
AU2003239393A1 (en) 2003-11-11
PT1507554E (pt) 2011-11-21
AU2003273182B8 (en) 2009-05-07
WO2003099323A1 (en) 2003-12-04
JP2011079858A (ja) 2011-04-21
JP2005533029A (ja) 2005-11-04

Similar Documents

Publication Publication Date Title
CN100467060C (zh) 通过瘤内施用乳铁蛋白治疗恶性肿瘤疾病的用途
JP2020023547A (ja) 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法
US20110110983A1 (en) Lactoferrin as an adjuvant in cancer vaccines
CN104688720A (zh) 绿原酸在制备治疗黑色素瘤的药物中的用途及治疗黑色素瘤的药物
CN1895237B (zh) 和厚朴酚脂质体冻干粉制剂及其在制备治疗恶性肿瘤药物中的应用
TWI725947B (zh) 巴豆酯組成物及用於治療或減少血球細胞減少期間之用途
CN101229175A (zh) 一对原人参二醇衍生物和它们混合体的医药用途
ES2368214T3 (es) Lactoferrina en el tratamiento de neoplasmas malignos y de otras enfermedades hiperproliferativas.
HK1083203B (en) The use of intratumorally administered lactoferrin in the treatment of malignant neoplasms
HK1080722B (en) The use of lactoferrin in the treatment of malignant neoplasms
ten Hagen Liposomal cytokines in the treatment of infectious diseases and cancer
CN116059322A (zh) 一种治疗和预防肿瘤的口服制剂及其制备方法
Taradi et al. Effect of thermoimmunotherapy with OK-432 on the development of spontaneous lung metastases in mice

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083203

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1083203

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090311

Termination date: 20140509